Patent · US Active

Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

US9066979B2 · kind B2 · utility

2Cited by

2References

16Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

David Yunzhi Li · Shanghai, CN
Jiabing Wang · Lansdale, US
Zhenfan Yang · Shanghai, CN
Qingbei Zeng · Shanghai, CN
Xiaolin Zhang · Singapore, SG

Key dates

Filing date	Mar 5, 2014
Grant date	Jun 30, 2015
Priority date	—
Expiry date	Mar 5, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof:which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.